Pregabalin Capsule
Product Images NDC 67877-467

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 67877-467). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 100 90

Pregabalin Capsules 100 mg oral capsules label from Ascend Laboratories, LLC. The label states each hard gelatin capsule contains 100 mg pregabalin, provides storage instructions, and indicates the package contains 90 capsules. It lists Alkem Laboratories, Ltd., India as the manufacturer and Ascend Laboratories, LLC as the distributor in Parsippany, NJ. The label includes a barcode and prescription-only designation.*

FDA Label Image

Pregabalin 150 90

Pregabalin Capsules 150 mg oral capsules label from Ascend Laboratories, LLC. The label indicates each hard gelatin capsule contains 150 mg of pregabalin. It includes storage instructions, dispensing guidelines, and states the package contains 90 capsules, Rx only. Manufacturer is Alkem Laboratories, Ltd., India, distributed by Ascend Laboratories, LLC, Parsippany, NJ.*

FDA Label Image

Pregabalin 200 500

Label for Pregabalin Capsules 200 mg in oral capsule form, manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC. The label indicates 500 capsules per container and includes storage instructions and dispensing guidance. The label also features the Rx only designation and a barcode.*

FDA Label Image

Pregabalin 225 90

Label for Pregabalin Capsules containing 225 mg of pregabalin. The label includes directions for dispensing and storage information, states the quantity of 90 capsules, and displays the labeler as Ascend Laboratories, LLC. The design features the product name prominently with the strength highlighted in yellow, along with barcode and manufacturer information.*

FDA Label Image

Pregabalin 25 90

Label for Pregabalin Capsules 25 mg oral capsules by Ascend Laboratories, LLC. The label states each hard gelatin capsule contains 25 mg pregabalin, packaged in a container with 90 capsules. It includes storage instructions, manufacturer information (Alkem Laboratories Ltd., India), and dispensing instructions emphasizing the accompanying Medication Guide. The label features the NDC 67877-462-90 and a barcode.*

FDA Label Image

Pregabalin 300 90

Label for Pregabalin Capsules 300 mg by Ascend Laboratories, LLC. The label includes usage instructions, storage conditions, and distribution details. It specifies 90 capsules in the container, with manufacturing by Alkem Laboratories Ltd., India. The NDC is 67877-469-90 and a barcode is displayed.*

FDA Label Image

Pregabalin 50 500

Label for Pregabalin Capsules 50 mg in capsule form, containing 500 capsules. The label states each capsule contains 50 mg pregabalin, with storage instructions and dispensing guidance included. Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ. The label also features the Ascend Laboratories logo and a barcode.*

FDA Label Image

Pregabalin 75 10

Label sheet featuring multiple repeat labels for Pregabalin 75 mg capsules, an oral human prescription drug distributed by Ascend Laboratories, LLC, Parsippany, NJ. Each label includes a barcode, text indicating the drug name, strength, capsule dosage form, distribution details, and statements that the product is made in India. Spaces for lot number and expiration date are visible but unfilled.*

FDA Label Image

Pregabalin 75 100

Packaging label for Pregabalin Capsules 75 mg by Ascend Laboratories, LLC. The label shows the 75 mg strength prominently in red, indicates the product is Rx only, and contains 100 capsules in unit-dose packaging. Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, with adjustment for female patients by multiplying by 0.85. The formula is presented as an equation with variables and constants.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar chart comparing responder rates (%) across different dosages of pregabalin in two studies (E1 and E3). The x-axis shows placebo and various pregabalin doses (50 mg/day to 600 mg/day), with administration frequencies (BID or TID) noted. The y-axis represents responder rates from 0% to 60%. Higher doses generally show increased responder rates, with statistical significance indicated versus placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as the median percentage change from baseline versus dose in mg/day. The graph shows data from multiple studies (E1 BID, E2 TID, E3 BID, E3 TID) with dose ranging from 0 (placebo) to about 450 mg/day. Significant p-values are annotated at various dose points, illustrating the seizure reduction trends associated with increasing doses.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline. The graph compares Pregabalin at different dosages (25 mg, 100 mg, and 200 mg, each taken three times a day) and placebo, showing varying levels of patient improvement across pain reduction percentages.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 12, contrasting Pregabalin and Placebo groups. The x-axis represents percent improvement from baseline to week 12, and the y-axis shows the percent of subjects improved. Pregabalin's line demonstrates higher improvement percentages compared to Placebo throughout the range.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph showing the percentage of subjects improved over time from baseline to week 16 based on BOCF (Baseline Observation Carried Forward) analysis. Two lines compare Pregabalin and placebo, depicting a higher percentage of improvement with Pregabalin across the timeline.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares two groups: one treated with Pregabalin 100 mg three times a day and a placebo group, illustrating efficacy differences in pain improvement between the treatments.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline, comparing Pregabalin capsules at dosages of 75 mg, 150 mg, and 300 mg taken twice a day versus placebo. The graph illustrates trends of increasing patient improvement with higher dosages of Pregabalin.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg and 200 mg taken three times a day versus placebo. The graph shows three lines representing the treatment groups, illustrating the effectiveness at varying levels of pain improvement.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It includes three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo group, showing the trends of pain improvement across these treatment groups.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three Pregabalin daily doses (600 mg, 450 mg, 300 mg) and a placebo, with each dose represented by separate lines tracking patient response across the improvement spectrum.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A line chart comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The x-axis represents Days, and the y-axis shows the estimated percentage of subjects without LTR from 0% to 100%. Two lines are plotted: one solid line for Pregabalin and one dashed line for Placebo, demonstrating differences in survival without LTR over time.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin displaying its molecular framework, including the amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.